Molecular dynamics (MD) simulations have become increasingly useful in the modern drug
development process. In this review, we give a broad overview of the current application …

One of the most common drivers in human cancer is the mutant KRAS protein. Not so long
ago KRAS was considered as an undruggable oncoprotein. After a long struggle, however …

The first step of RAF activation involves binding to active RAS, resulting in the recruitment of
RAF to the plasma membrane. To understand the molecular details of RAS-RAF interaction …

Despite the prominent role of the K-Ras protein in many different types of human cancer,
major gaps in atomic-level information severely limit our understanding of its functions in …

Members of the family of RAS proto-oncogenes, discovered just over 40 years ago, were
among the first cancer-initiating genes to be discovered. Of the three RAS family members …

RAS is the most frequently mutated oncogene in cancer and a critical driver of oncogenesis.
Therapeutic targeting of RAS has been a goal of cancer research for more than 30 years …

The RAS GTPases are frequently mutated in human cancer, with KRAS being the
predominant tumor driver. For many years, it has been known that the structure and function …

Mutations in K-Ras are involved in a large number of all human cancers, thus, K-Ras is
regarded as a promising target for anticancer drug design. Understanding the target roles of …

The most commonly mutated isoform of RAS among all cancer subtypes is KRAS. In this
review, we focus on the special role of KRAS mutations in colorectal cancer (CRC), aiming …

RAS proteins are molecular switches that interact with effector proteins when bound to
guanosine triphosphate, stimulating downstream signaling in response to multiple stimuli …